サマリー

市場分析・洞察：医薬品CDMO（医薬品開発・製造受託機関）の世界市場
COVID-19パンデミックとロシア・ウクライナ戦争の影響により、2023年に139345百万米ドルと推定される医薬品CDMO（医薬品開発・製造受託機関）の世界市場は、2029年までに217203百万米ドルの改定規模に達し、予測期間2023-2029年にCAGR 7.68% で成長すると予測します。
医薬品CDMO（医薬品開発・製造受託機関）の米国・カナダ市場は、2023年の37855百万ドルから2029年には50454百万ドルに達し、2023年から2029年の予測期間中にCAGR4.9％で増加すると予測しています。
医薬品CDMO（医薬品開発・製造受託機関）の中国市場は、2023年の17129百万ドルから2029年には51175百万ドルに達すると推定され、2023年から2029年の予測期間中に20.01%のCAGRで増加すると予測されます。
欧州の医薬品CDMO（医薬品開発・製造受託機関）市場は、2023年の28502百万ドルから2029年には36462百万ドルに達し、2024年から2029年の予測期間中に4.19%のCAGRで増加すると推定されます。
医薬品CDMO（医薬品開発・製造受託機関）の世界の主要企業は、Lonza、Catalent、Thermo Fisher Scientific、Samsung Biologics、Fareva、WuXi AppTech、WuXi Biologics、Siegfried、FUJIFILM Diosynth Biotechnologies、Asychemなど。2022年、世界の上位5社の売上高シェアは約14.45%でした。

レポートには、以下の内容が含まれます。
本レポートでは、医薬品CDMO（医薬品開発・製造受託機関）の世界市場規模を概観しています。2018年～2022年の過去の市場収益データ、2023年の予測、2029年までのCAGRの予測など、世界市場の動向を分析します。
本レポートでは、医薬品CDMO（医薬品開発・製造受託機関）の主要生産者を調査し、主要地域や国の収益も掲載しています。医薬品CDMO（医薬品開発・製造受託機関）の今後の市場可能性のハイライトと、この市場を様々なセグメントとサブセグメントに分けて予測するための主要地域/国への注目点。米国、カナダ、メキシコ、ブラジル、中国、日本、韓国、東南アジア、インド、ドイツ、英国、イタリア、中東、アフリカ、その他諸国の国別データおよび市場価値分析。

本レポートでは、2018年から2023年のデータをもとに、医薬品CDMO（医薬品開発・製造受託機関）の収益、主要企業の市場シェア、業界ランキングに焦点を当てます。世界の医薬品CDMO（医薬品開発・製造受託機関）市場における主要なステークホルダーを特定し、その競争環境と市場ポジショニングを最近の動向とセグメント別の収益に基づき分析します。本レポートは、関係者が競争環境を理解し、より多くの洞察を得て、事業と市場戦略をより良い方法で位置づけるのに役立ちます。
本レポートでは、2018年から2029年までの、タイプ別、用途別のセグメントデータ、収益、成長率を分析しています。医薬品CDMO（医薬品開発・製造受託機関）の収益、予測される成長動向、生産技術、アプリケーション、エンドユーザー産業の評価と市場規模を予測します。
Lonza、Catalent、Thermo Fisher Scientific、Aenova、Siegfried、Recipharm、Strides Pharma、Piramal、Boehringer Ingelheimなど、世界の主要プレイヤーの説明付き企業プロフィール。

会社別
キャタレント
サーモフィッシャーサイエンティフィック
ロンザ
ジークフリート
レシプファーム
ベーリンガーインゲルハイム
呉西AppTech
ウーシーバイオロジクス（WuXi Biologics
ファレバ
サムスンバイオロジクス
アエノバ
デルファルム
ストレイズファーマ
ピラマル
ファマー
キュリア
ジュビラント
ベター
AGCファーマケミカルズ
アシムケム
ポートン
ユーロフィンズ
アセンダイヤ・ファーマシューティカルズ
アルデナ
シーピーエル
UPMファーマシューティカルズ
富士フイルムジオシンセ・バイオテクノロジーズ
グループ・パリマ
TBD ファーマテック
アビッドバイオサービシズ
ネクストファーマ
アルカミ
ソシアルCDMO
メドファーム
ユーロアピ
バイオベクトラ
ファイザーCentreOne
フェルミ粒子
ルンドベック

タイプ別セグメント
API CDMO
FDF CDMO
パッケージングCDMO
クリニカルCDMO

アプリケーション別セグメント
製薬会社
バイオテクノロジー企業
その他

地域別
北アメリカ
ユーエスエー
カナダ

アジア（中国を除く）
日本
南朝鮮
東南アジア
インド
オーストラリア
その他のアジア
中国

ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
その他のヨーロッパ

中南米・中東・アフリカ
メキシコ
ブラジル
中近東
アフリカ
その他

章立て
第1章：報告書のスコープ、各市場セグメント（製品タイプ、アプリケーション）の市場規模、将来の発展可能性などのエグゼクティブサマリーを紹介します。市場の現状と短・中期・長期の展開の可能性を高いレベルで把握することができます。
第2章 医薬品CDMO（医薬品開発・製造受託機関）の世界・地域レベルでの収益。各地域とその主要国の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来の発展見通し、市場スペース、生産能力などを紹介しています。また、市場力学、市場の最新動向、市場の推進要因と制限要因、業界各社が直面する課題とリスク、業界の関連政策の分析などを紹介します。
第3章：医薬品CDMO（医薬品開発・製造受託機関）企業鈥の競争環境、収益、市場シェア、業界ランキング、最新の開発計画、M&A情報などの詳細分析。
第4章：各種市場セグメントをタイプ別に分析し、各市場セグメントの収益、発展可能性を網羅し、読者が異なる市場セグメントでブルーオーシャン市場を見つけるのに役立つ情報を提供します。
第5章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの収益、開発可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。
第6章：北米（米国・カナダ）タイプ別、アプリケーション別、国別、各セグメント別の収益。
第7章：ヨーロッパ：タイプ別、アプリケーション別、国別、各セグメント別収益。
第8章：中国：タイプ別、アプリケーション別、セグメント別収益。
第9章：アジア（中国を除く）：タイプ別、アプリケーション別、地域別、各セグメントごとの収益。
第10章：中東、アフリカ、中南米 タイプ別、アプリケーション別、国別、各セグメントごとの収益。
第11章：主要企業のプロファイルを提供し、製品の説明や仕様、医薬品CDMO（医薬品開発・製造受託機関）の収益、粗利益率、最近の開発など、市場の主要企業の基本状況を詳細に紹介する。
第12章 アナリストの視点/結論

ページTOPに戻る

目次

1 Report Overview 1
1.1 Study Scope 1
1.2 Market Analysis by Type 1
1.2.1 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size Growth Rate by Type: 2018 VS 2022 VS 2029 1
1.2.2 Clinical CDMO 4
1.2.3 API CDMO 4
1.2.4 FDF CDMO 4
1.2.5 Packaging CDMO 5
1.3 Market by Application 6
1.3.1 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Application: 2018 VS 2022 VS 2029 6
1.3.2 Pharmaceutical Company 9
1.3.3 Biotechnology Company 9
1.4 Assumptions and Limitations 9
1.5 Study Objectives 10
1.6 Years Considered 11
2 Global Growth Trends 12
2.1 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Perspective (2018-2029) 12
2.2 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Growth Trends by Region 14
2.2.1 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Region: 2018 VS 2022 VS 2029 15
2.2.2 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Historic Market Size by Region (2018-2023) 16
2.2.3 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Forecasted Market Size by Region (2024-2029) 17
2.3 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Dynamics 18
2.3.1 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Industry Trends 18
2.3.2 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Drivers 20
2.3.3 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Challenges 21
2.3.4 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Restraints 22
3 Competition Landscape by Key Players 23
3.1 Global Revenue Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) by Players 23
3.1.1 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue by Players (2018-2023) 23
3.1.2 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue Market Share by Players (2018-2023) 25
3.2 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) by Company Type (Tier 1, Tier 2, and Tier 3) 28
3.3 Global Key Players of Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization), Ranking by Revenue, 2021 VS 2022 29
3.4 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Concentration Ratio 32
3.4.1 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Concentration Ratio (CR5 and HHI) 32
3.4.2 Global Top 10 and Top 5 Companies by Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue in 2022 33
3.5 Global Key Players of Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Head office and Production Site 34
3.6 Founded Date of Global Key Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Players 36
3.7 Mergers & Acquisitions, Expansion Plans 38
4 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Breakdown Data by Type 41
4.1 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Historic Market Size by Type (2018-2023) 41
4.2 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Forecasted Market Size by Type (2024-2029) 42
5 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Breakdown Data by Application 44
5.1 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Historic Market Size by Application (2018-2023) 44
5.2 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Forecasted Market Size by Application (2024-2029) 45
6 North America 46
6.1 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size (2018-2029) 46
6.2 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type 47
6.2.1 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2018-2023) 47
6.2.2 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2024-2029) 47
6.2.3 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Type (2018-2029) 48
6.3 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application 49
6.3.1 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2018-2023) 49
6.3.2 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2024-2029) 49
6.3.3 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Application (2018-2029) 50
6.4 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country 51
6.4.1 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country: 2018 VS 2022 VS 2029 51
6.4.2 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country (2018-2023) 51
6.4.3 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Country (2024-2029) 52
6.4.4 United States 53
6.4.5 Canada 53
7 Europe 54
7.1 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size (2018-2029) 54
7.2 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type 55
7.2.1 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2018-2023) 55
7.2.2 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2024-2029) 55
7.2.3 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Type (2018-2029) 56
7.3 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application 57
7.3.1 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2018-2023) 57
7.3.2 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2024-2029) 57
7.3.3 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Application (2018-2029) 58
7.4 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country 59
7.4.1 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country: 2018 VS 2022 VS 2029 59
7.4.2 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country (2018-2023) 59
7.4.3 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country (2024-2029) 60
7.4.4 Germany 61
7.4.5 France 62
7.4.6 U.K. 62
7.4.7 Italy 63
7.4.8 Russia 63
8 China 64
8.1 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size (2018-2029) 64
8.2 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type 65
8.2.1 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2018-2023) 65
8.2.2 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2024-2029) 65
8.2.3 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Type (2018-2029) 66
8.3 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application 67
8.3.1 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2018-2023) 67
8.3.2 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2024-2029) 67
8.3.3 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Application (2018-2029) 68
9 Asia (excluding China) 69
9.1 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size (2018-2029) 69
9.2 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type 70
9.2.1 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2018-2023) 70
9.2.2 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2024-2029) 70
9.2.3 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Type (2018-2029) 71
9.3 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application 71
9.3.1 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2018-2023) 71
9.3.2 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2024-2029) 72
9.3.3 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Application (2018-2029) 73
9.4 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Region 74
9.4.1 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Region: 2018 VS 2022 VS 2029 74
9.4.2 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Region (2018-2023) 74
9.4.3 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Region (2024-2029) 75
9.4.4 Japan 76
9.4.5 South Korea 77
9.4.6 Southeast Asia 77
9.4.7 India 78
9.4.8 Australia 78
10 Middle East, Africa, and Latin America 79
10.1 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size (2018-2029) 79
10.2 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type 80
10.2.1 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2018-2023) 80
10.2.2 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2024-2029) 80
10.2.3 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Type (2018-2029) 81
10.3 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application 82
10.3.1 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2018-2023) 82
10.3.2 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2024-2029) 82
10.3.3 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Application (2018-2029) 83
10.4 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country 84
10.4.1 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country: 2018 VS 2022 VS 2029 84
10.4.2 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country (2018-2023) 84
10.4.3 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country (2024-2029) 85
10.4.4 Brazil 86
10.4.5 Mexico 87
10.4.6 Middle East 87
10.4.7 Africa 88
11 Key Players Profiles 89
11.1 Catalent 89
11.1.1 Catalent Company Details 89
11.1.2 Catalent Business Overview 89
11.1.3 Catalent Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 91
11.1.4 Catalent Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 93
11.1.5 Catalent Recent Development 93
11.2 Thermo Fisher Scientific 94
11.2.1 Thermo Fisher Scientific Company Details 94
11.2.2 Thermo Fisher Scientific Business Overview 94
11.2.3 Thermo Fisher Scientific Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 95
11.2.4 Thermo Fisher Scientific Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 97
11.2.5 Thermo Fisher Scientific Recent Development 97
11.3 Lonza 97
11.3.1 Lonza Company Details 97
11.3.2 Lonza Business Overview 98
11.3.3 Lonza Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 100
11.3.4 Lonza Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 101
11.3.5 Lonza Recent Development 101
11.4 Siegfried 102
11.4.1 Siegfried Company Details 102
11.4.2 Siegfried Business Overview 102
11.4.3 Siegfried Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 103
11.4.4 Siegfried Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 105
11.4.5 Siegfried Recent Development 105
11.5 Recipharm 105
11.5.1 Recipharm Company Details 105
11.5.2 Recipharm Business Overview 106
11.5.3 Recipharm Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 107
11.5.4 Recipharm Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 108
11.5.5 Recipharm Recent Development 109
11.6 Boehringer Ingelheim 109
11.6.1 Boehringer Ingelheim Company Details 109
11.6.2 Boehringer Ingelheim Business Overview 110
11.6.3 Boehringer Ingelheim Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 110
11.6.4 Boehringer Ingelheim Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 111
11.6.5 Boehringer Ingelheim Recent Development 111
11.7 WuXi AppTech 112
11.7.1 WuXi AppTech Company Details 112
11.7.2 WuXi AppTech Business Overview 113
11.7.3 WuXi AppTech Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 113
11.7.4 WuXi AppTech Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 114
11.7.5 WuXi AppTech Recent Development 114
11.8 WuXi Biologics 115
11.8.1 WuXi Biologics Company Details 115
11.8.2 WuXi Biologics Business Overview 115
11.8.3 WuXi Biologics Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 116
11.8.4 WuXi Biologics Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 117
11.8.5 WuXi Biologics Recent Development 117
11.9 Fareva 118
11.9.1 Fareva Company Details 118
11.9.2 Fareva Business Overview 118
11.9.3 Fareva Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 119
11.9.4 Fareva Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 119
11.9.5 Fareva Recent Development 120
11.10 Samsung Biologics 120
11.10.1 Samsung Biologics Company Details 120
11.10.2 Samsung Biologics Business Overview 121
11.10.3 Samsung Biologics Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 121
11.10.4 Samsung Biologics Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 122
11.10.5 Samsung Biologics Recent Development 123
11.11 Aenova 123
11.11.1 Aenova Company Details 123
11.11.2 Aenova Business Overview 124
11.11.3 Aenova Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 124
11.11.4 Aenova Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 126
11.11.5 Aenova Recent Development 127
11.12 Delpharm 127
11.12.1 Delpharm Company Details 127
11.12.2 Delpharm Business Overview 128
11.12.3 Delpharm Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 128
11.12.4 Delpharm Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 130
11.12.5 Delpharm Recent Development 130
11.13 Strides Pharma 131
11.13.1 Strides Pharma Company Details 131
11.13.2 Strides Pharma Business Overview 131
11.13.3 Strides Pharma Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 132
11.13.4 Strides Pharma Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 133
11.13.5 Strides Pharma Recent Development 133
11.14 Piramal 133
11.14.1 Piramal Company Details 133
11.14.2 Piramal Business Overview 134
11.14.3 Piramal Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 135
11.14.4 Piramal Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 135
11.14.5 Piramal Recent Development 136
11.15 Famar 136
11.15.1 Famar Company Details 136
11.15.2 Famar Business Overview 137
11.15.3 Famar Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 137
11.15.4 Famar Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 138
11.15.5 Famar Recent Development 139
11.16 Curia 139
11.16.1 Curia Company Details 139
11.16.2 Curia Business Overview 140
11.16.3 Curia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 140
11.16.4 Curia Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 141
11.16.5 Curia Recent Development 141
11.17 Jubilant 142
11.17.1 Jubilant Company Details 142
11.17.2 Jubilant Business Overview 142
11.17.3 Jubilant Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 143
11.17.4 Jubilant Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 144
11.17.5 Jubilant Recent Development 144
11.18 Vetter Pharma 145
11.18.1 Vetter Pharma Company Details 145
11.18.2 Vetter Pharma Business Overview 145
11.18.3 Vetter Pharma Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 146
11.18.4 Vetter Pharma Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 146
11.18.5 Vetter Pharma Recent Development 146
11.19 AGC Pharma Chemicals 147
11.19.1 AGC Pharma Chemicals Company Details 147
11.19.2 AGC Pharma Chemicals Business Overview 148
11.19.3 AGC Pharma Chemicals Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 148
11.19.4 AGC Pharma Chemicals Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 150
11.19.5 AGC Pharma Chemicals Recent Development 150
11.20 Asymchem 151
11.20.1 Asymchem Company Details 151
11.20.2 Asymchem Business Overview 151
11.20.3 Asymchem Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 152
11.20.4 Asymchem Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 153
11.20.5 Asymchem Recent Development 153
11.21 Porton 154
11.21.1 Porton Company Details 154
11.21.2 Porton Business Overview 154
11.21.3 Porton Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 155
11.21.4 Porton Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 156
11.21.5 Porton Recent Development 156
11.22 Eurofins 156
11.22.1 Eurofins Company Details 156
11.22.2 Eurofins Business Overview 157
11.22.3 Eurofins Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 158
11.22.4 Eurofins Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 159
11.22.5 Eurofins Recent Development 159
11.23 Ascendia Pharmaceuticals 160
11.23.1 Ascendia Pharmaceuticals Company Details 160
11.23.2 Ascendia Pharmaceuticals Business Overview 160
11.23.3 Ascendia Pharmaceuticals Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 161
11.23.4 Ascendia Pharmaceuticals Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 161
11.23.5 Ascendia Pharmaceuticals Recent Development 162
11.24 Ardena 162
11.24.1 Ardena Company Details 162
11.24.2 Ardena Business Overview 163
11.24.3 Ardena Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 163
11.24.4 Ardena Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 164
11.24.5 Ardena Recent Development 164
11.25 CPL 165
11.25.1 CPL Company Details 165
11.25.2 CPL Business Overview 165
11.25.3 CPL Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 166
11.25.4 CPL Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 166
11.25.5 CPL Recent Development 166
11.26 UPM Pharmaceuticals 167
11.26.1 UPM Pharmaceuticals Company Details 167
11.26.2 UPM Pharmaceuticals Business Overview 167
11.26.3 UPM Pharmaceuticals Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 168
11.26.4 UPM Pharmaceuticals Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 168
11.26.5 UPM Pharmaceuticals Recent Development 169
11.27 FUJIFILM Diosynth Biotechnologies 169
11.27.1 FUJIFILM Diosynth Biotechnologies Company Details 169
11.27.2 FUJIFILM Diosynth Biotechnologies Business Overview 170
11.27.3 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 170
11.27.4 FUJIFILM Diosynth Biotechnologies Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 171
11.27.5 FUJIFILM Diosynth Biotechnologies Recent Development 171
11.28 Groupe Parima 172
11.28.1 Groupe Parima Company Details 172
11.28.2 Groupe Parima Business Overview 172
11.28.3 Groupe Parima Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 173
11.28.4 Groupe Parima Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 174
11.29 TBD Pharmatech 174
11.29.1 TBD Pharmatech Company Details 174
11.29.2 TBD Pharmatech Business Overview 175
11.29.3 TBD Pharmatech Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 175
11.29.4 TBD Pharmatech Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 176
11.30 Avid Bioservices 176
11.30.1 Avid Bioservices Company Details 176
11.30.2 Avid Bioservices Business Overview 177
11.30.3 Avid Bioservices Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 177
11.30.4 Avid Bioservices Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 178
11.31 NextPharma 178
11.31.1 NextPharma Company Details 178
11.31.2 NextPharma Business Overview 179
11.31.3 NextPharma Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 180
11.31.4 NextPharma Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 181
11.31.5 NextPharma Recent Development 182
11.32 Alcami 183
11.32.1 Alcami Company Details 183
11.32.2 Alcami Business Overview 183
11.32.3 Alcami Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 184
11.32.4 Alcami Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 186
11.32.5 Alcami Recent Development 186
11.33 Societal CDMO 186
11.33.1 Societal CDMO Company Details 186
11.33.2 Societal CDMO Business Overview 187
11.33.3 Societal CDMO Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 188
11.33.4 Societal CDMO Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 189
11.33.5 Societal CDMO Recent Development 189
11.34 MedPharm 190
11.34.1 MedPharm Company Details 190
11.34.2 MedPharm Business Overview 191
11.34.3 MedPharm Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 192
11.34.4 MedPharm Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 192
11.35 Euroapi 193
11.35.1 Euroapi Company Details 193
11.35.2 Euroapi Business Overview 193
11.35.3 Euroapi Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 194
11.35.4 Euroapi Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 195
11.35.5 Euroapi Recent Development 195
11.36 BioVectra 196
11.36.1 BioVectra Company Details 196
11.36.2 BioVectra Business Overview 197
11.36.3 BioVectra Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 198
11.36.4 BioVectra Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 199
11.37 Pfizer CentreOne 199
11.37.1 Pfizer CentreOne Company Details 199
11.37.2 Pfizer CentreOne Business Overview 200
11.37.3 Pfizer CentreOne Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 200
11.37.4 Pfizer CentreOne Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 201
11.37.5 Pfizer CentreOne Recent Development 201
11.38 Fermion 202
11.38.1 Fermion Company Details 202
11.38.2 Fermion Business Overview 203
11.38.3 Fermion Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 205
11.38.4 Fermion Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 206
11.38.5 Fermion Recent Development 206
11.39 Lundbeck 207
11.39.1 Lundbeck Company Details 207
11.39.2 Lundbeck Business Overview 208
11.39.3 Lundbeck Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 209
11.39.4 Lundbeck Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 211
11.39.5 Lundbeck Recent Development 211
12 Analyst's Viewpoints/Conclusions 213
13 Appendix 216
13.1 Research Methodology 216
13.1.1 Methodology/Research Approach 216
13.1.2 Data Source 219
13.2 Author Details 222
13.3 Disclaimer 224